Rituximab in cutaneous B-cell lymphoma: a report of two cases

• DOI: 10.1046/j.1365-2133.2000.03607.x
• Publication Date: 2003-03-11T05:28:57Z
• Authors: R.A. Sabroe; F.J. Child; A.J. Woolford; M.F. Spittle; R. Russell-Jones
• Keywords: Follicular lymphoma

We report two patients with primary cutaneous B-cell lymphoma who were treated rituximab, a new anti-CD20 monoclonal antibody. The first patient, had diffuse large of the lower leg, achieved an 85% improvement. second lymphoma, which undergone high-grade transformation and systemic spread, minor response approximately 30%. Both subsequently relapsed. patient complete clearance course rituximab given chemotherapy, but again Treatment has been reported to produce rates 48% in relapsed low-grade or follicular there are no previous reports use lymphoma.